Anti-CLEC12A Antibody, Non-Fucosylated (BioBet-720ZP) (CAT#: BioBet-720ZP) Datasheet

CLEC12A

C-type lectin domain family 12, member A

This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signaling, glycoprotein turnover, and roles in inflammation and immune response. The protein encoded by this gene is a negative regulator of granulocyte and monocyte function. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined. This gene is closely linked to other CTL/CTLD superfamily members in the natural killer gene complex region on chromosome 12p13.

CLEC12A; C-type lectin domain family 12, member A; CLL1; MICL; CLL-1; DCAL-2; C-type lectin domain family 12 member A; C-type lectin protein CLL-1; C-type lectin-like molecule-1; dendritic cell-associated lectin 2; myeloid inhibitory C-type lectin-like receptor

Plasma membrane

Diseases associated with CLEC12A include Coffin-Siris Syndrome 2 and 3Mc Syndrome.

Its related pathways are Innate Immune System and C-type lectin receptor signaling pathway.

Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases.

Highly N-glycosylated. Glycosylation varies between cell types.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-720ZP

Chimeric

Human

This is an antibodiy that specifically bind to human CLL-1, in particular to the extracellular domain of a CLL-1 expressing cell. The CLL-1 antibody can inhibit cancer cell growth (proliferation and/or engraftment) and thus can be considered chemotherapeutic agents alone.

Hematologic malignancies

Hematologic malignancies